

JOHAN ASKLING PUBLICATIONS 2017**Peer reviewed articles**

1. Arkema EV, Askling J, Salmon JE, Simard JF. Sex Ratio of Offspring Born to Women With Systemic Lupus Erythematosus or Rheumatoid Arthritis. *Arthritis & Rheumatology*. 2017;69(1):143-7.
2. Askling J, Holmqvist M, Ljung L. Is Rheumatoid Arthritis a Mortal Disease? *Arthritis & Rheumatology*. 2017;69(8):1509-11.
3. Baecklund F, Foo JN, Askling J, Eloranta S, Glimelius I, Liu JJ, et al. Possible Interaction Between Cigarette Smoking and HLA-DRB1 Variation in the Risk of Follicular Lymphoma. *American Journal of Epidemiology*. 2017;185(8):681-7.
4. Bengtsson K, Forsblad-d'Elia H, Lie E, Klingberg E, Dehlin M, Exarchou S, et al. HOW STRONG ARE THE ASSOCIATIONS OF SPONDYLOARTHRITIS-RELATED COMORBIDITIES WITH ANKYLOSING SPONDYLITIS, PSORIATIC ARTHRITIS AND UNDIFFERENTIATED SPONDYLOARTHRITIS? A REGISTER-BASED STUDY FROM SWEDEN. *Annals of the Rheumatic Diseases*. 2017;76:154-5.
5. Bengtsson K, Forsblad-d'Elia H, Lie E, Klingberg E, Dehlin M, Exarchou S, et al. Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study. *Arthritis Research & Therapy*. 2017;19.
6. Chatzidionysiou K, Aaltonen K, Nordstrom D, Gudbjornsson B, Grondal G, Geirsson AJ, et al. HOW DO WE USE BIOLOGICS IN PATIENTS WITH A HISTORY OF MALIGNANCY? AN ASSESSMENT OF TREATMENT PATTERNS USING SCANDINAVIAN REGISTERS. *Annals of the Rheumatic Diseases*. 2017;76:1027-.
7. Di Giuseppe D, Frisell T, Ernestam S, Forsblad-d'Elia H, Lindqvist E, Lindstrom U, et al. ASSESSMENT OF BIOSIMILARS USING REAL WORLD DATA: THE COMPLEXITY OF CHOOSING A COMPARATOR AND UNDERSTANDING UPTAKE. *Annals of the Rheumatic Diseases*. 2017;76:452-3.
8. Di Giuseppe D, Johansson K, Askling J, Alfredsson L. Mediterranean Diet Is Inversely Associated with Risk of Rheumatoid Arthritis: A Swedish Population Based Case-Control Study. *Arthritis & Rheumatology*. 2017;69.
9. Eberhardson M, Soderling JK, Neovius M, Cars T, Myrelid P, Ludvigsson JF, et al. Anti-TNF treatment in Crohn's disease and risk of bowel resection-a population based cohort study. *Alimentary Pharmacology & Therapeutics*. 2017;46(6):589-98.
10. Eriksson JK, Jacobsson L, Bengtsson K, Askling J. Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis? *Annals of the Rheumatic Diseases*. 2017;76(2):364-70.

11. Finckh A, Courvoisier D, Gottenberg JE, Marlette X, Morel J, Bergstra SA, et al. DOES SEROPOSITIVITY INFLUENCE DIFFERENTIALLY DRUG DISCONTINUATION OF BIOLOGIC ANTIRHEUMATIC AGENTS WITH NON-ANTI-TNF MODE OF ACTION? *Annals of the Rheumatic Diseases*. 2017;76:567-.
12. Frisell T, Baecklund E, Bengtsson K, Di Giuseppe D, Forsblad-d'Elia H, Askling J, et al. CONFOUNDING BY INDICATION WILL MAKE NON-TNFI BDMARDS APPEAR MORE HARMFUL THAN TNFI BDMARDS A NATIONWIDE STUDY OF CHANNELING IN SWEDEN 2010-2014. *Annals of the Rheumatic Diseases*. 2017;76:134-5.
13. Frisell T, Dehlin M, Di Giuseppe D, Feltelius N, Kastbom A, Turesson C, et al. COMPARATIVE EFFECTIVENESS OF ABATACEPT, RITUXIMAB, TOCILIZUMAB AND ANTI-TNF BIOLOGICAL DMARDS IN RA: RESULTS FROM THE NATIONWIDE SWEDISH REGISTER. *Annals of the Rheumatic Diseases*. 2017;76:563-.
14. Glintborg B, Lindstrom U, Aaltonen K, Kristianslund EK, Gudbjornsson B, Chatzidionysiou K, et al. First Line Biological Treatment in Ankylosing Spondylitis, Prescription Rates, Baseline Demographics and Disease Activity. a Collaboration between Biological Registers in the Five Nordic Countries. *Arthritis & Rheumatology*. 2017;69.
15. Gron KL, Arkema EV, Glintborg B, Askling J, Hetland ML. Baseline Characteristics and Rates of Hospitalized Infections in Patients with Rheumatoid Arthritis Treated with Non-TNF Inhibitors in Denmark and Sweden. *Arthritis & Rheumatology*. 2017;69.
16. Hellgren K, Baecklund E, Backlin C, Sundstrom C, Smedby KE, Askling J. Rheumatoid Arthritis and Risk of Malignant Lymphoma. *Arthritis & Rheumatology*. 2017;69(4):700-8.
17. Hellgren K, Dreyer L, Arkema EV, Glintborg B, Jacobsson LTH, Kristensen LE, et al. Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers. *Annals of the Rheumatic Diseases*. 2017;76(1):105-11.
18. Hensvold AH, Frisell T, Magnusson PKE, Holmdahl R, Askling J, Catrina AI. How well do ACPA discriminate and predict RA in the general population: a study based on 12 590 population-representative Swedish twins. *Annals of the Rheumatic Diseases*. 2017;76(1):119-25.
19. Holmqvist M, Ljung L, Askling J. Acute coronary syndrome in new-onset rheumatoid arthritis: a population-based nationwide cohort study of time trends in risks and excess risks. *Annals of the Rheumatic Diseases*. 2017;76(10):1642-7.
20. Holmqvist M, Ljung L, Askling J. MORTALITY IN NEW-ONSET RHEUMATOID ARTHRITIS - HAS MODERN RHEUMATOLOGY HAD AN IMPACT? *Annals of the Rheumatic Diseases*. 2017;76:114-.

21. Ilar A, Wiebert P, Saevarsdottir S, Askling J, Gustavsson P, Alfredsson L. Occupational Exposure to Combustion Products and Risk of Developing Rheumatoid Arthritis. *Arthritis & Rheumatology*. 2017;69.
22. Lancelot M, Grimaud O, Saevarsdottir S, Askling J, Klareskog L, Alfredsson L, et al. Diet Change and Omega-3 Supplementation in the First Three Years Following a Diagnosis with Rheumatoid Arthritis in Sweden. *Arthritis & Rheumatology*. 2017;69.
23. Lie E, Lindstrom U, Zverkova-Sandstrom T, Olsen IC, Forsblad-d'Elia H, Askling J, et al. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register. *Annals of the Rheumatic Diseases*. 2017;76(9):1515-21.
24. Ludvigsson JF, Busch K, Olen O, Askling J, Smedby KE, Ekblom A, et al. Prevalence of paediatric inflammatory bowel disease in Sweden: a nationwide population-based register study. *Bmc Gastroenterology*. 2017;17.
25. Mantel A, Holmqvist M, Andersson DC, Lund LH, Askling J. Association Between Rheumatoid Arthritis and Risk of Ischemic and Nonischemic Heart Failure. *Journal of the American College of Cardiology*. 2017;69(10):1275-85.
26. Mantel A, Holmqvist M, Jernberg T, Wallberg-Jonsson S, Askling J. Long-term outcomes and secondary prevention after acute coronary events in patients with rheumatoid arthritis. *Annals of the Rheumatic Diseases*. 2017;76(12):2017-24.
27. Mercer LK, Askling J, Raaschou P, Dixon WG, Dreyer L, Hetland ML, et al. Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. *Annals of the Rheumatic Diseases*. 2017;76(2):386-91.
28. Mercer LK, Regierer AC, Mariette X, Dixon WG, Baecklund E, Hellgren K, et al. Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project. *Annals of the Rheumatic Diseases*. 2017;76(12):2025-30.
29. Olen O, Askling J, Frumento P, Sachs MC, Neovius M, Eriksson J, et al. Childhood-onset inflammatory bowel disease and risk of cancer - a Swedish nationwide cohort study 1964-2014. *Journal of Crohns & Colitis*. 2017;11:S14-S5.
30. Olen O, Askling J, Sachs MC, Frumento P, Neovius M, Smedby KE, et al. Childhood onset inflammatory bowel disease and risk of cancer: a Swedish nationwide cohort study 1964-2014. *Bmj-British Medical Journal*. 2017;358.
31. Olofsson T, Petersson IF, Eriksson JK, Englund M, Nilsson JA, Geborek P, et al. Predictors of work disability after start of anti-TNF therapy in a national cohort of Swedish patients with rheumatoid arthritis: does early anti-TNF therapy bring patients back to work? *Annals of the Rheumatic Diseases*. 2017;76(7):1245-52.
32. Raaschou P, Soderling J, Askling J, Grp AS. TNF INHIBITOR TREATMENT AND RISK OF CANCER RECURRENCE IN PATIENTS WITH RHEUMATOID ARTHRITIS: A NATIONWIDE COHORT STUDY FROM SWEDEN. *Annals of the Rheumatic Diseases*. 2017;76:183-.

33. Remaeus K, Johansson K, Askling J, Stephansson O. Juvenile onset arthritis and pregnancy outcome: a population-based cohort study. *Annals of the Rheumatic Diseases*. 2017;76(11):1809-14.
34. Turesson C, Frisell T, Dehlin M, Di Giuseppe D, Feltelius N, Kastbom A, et al. COMPARATIVE EFFECTIVENESS AT 1 YEAR OF DIFFERENT ANTI-TNF DRUGS AS FIRST BIOLOGIC DMARD IN PATIENTS WITH RHEUMATOID ARTHRITIS - RESULTS FROM THE NATIONWIDE SWEDISH REGISTER. *Annals of the Rheumatic Diseases*. 2017;76:57-.
35. Wadstrom H, Arkema EV, Sjowall C, Askling J, Simard JF. Cervical neoplasia in systemic lupus erythematosus: a nationwide study. *Rheumatology*. 2017;56(4):613-9.
36. Wadstrom H, Frisell T, Askling J, Anti-Rheumatic T. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice A Nationwide Cohort Study From Sweden. *Jama Internal Medicine*. 2017;177(11):1605-12.
37. Wadstrom H, Frisell T, Askling J, Grp AS. OVERALL CANCER RISK IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TNF INHIBITORS, TOCILIZUMAB, ABATACEPT, OR RITUXIMAB. *Annals of the Rheumatic Diseases*. 2017;76:93-.
38. Waldenlind K, Saevarsdottir S, Bengtsson C, Askling J. DOES THYROXIN SUBSTITUTION PREDICT NON-RESPONSE TO METHOTREXATE IN EARLY RA? *Annals of the Rheumatic Diseases*. 2017;76:537-8.